ArticleJournal of controlled release : official journal of the Controlled Release Society2025
Intracellular redistribution of cell-penetrating peptide p28: A mechanism for enhanced anti-cancer activity.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Suppression of mitochondrial energy production by a photosynthetic bacterial cupredoxin peptide inhibits tumor growth.Signal transduction and targeted therapy · 2026Article
- Integrating Computational and Experimental Approaches for the Discovery of Multifunctional Peptides from the Marine GastropodMarine drugs · 2026Article
- Intracellular Transport of Monomeric Peptides, (Poly)Peptide-Based Coacervates and Fibrils: Mechanisms and Prospects for Drug Delivery.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cell-penetrating peptides (CPPs) have been studied as they provide an efficient strategy for the intracellular delivery of bioactive molecules in various biomedical applications such as cancer diagnosis and therapy. We have developed an anionic CPP, p28, that can preferentially enter cancer cells and induce cell cycle arrest and apoptotic cell death preclinically and that showed preliminary efficacy in humans. Yet, the underlying intracellular fate after cell entry remains largely uncharacterized. To better understand the intracellular trafficking of p28, we investigated more closely the role of endosomal acidification and retrograde transport in cancer cells. Here, we show that agents such as chloroquine (CQ), NH
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.